This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Guilhou, J.-J. Articles by Dubeaux, D. Search for Related Content PubMed PubMed Citation Articles by Guilhou, J.-J. Articles by Dubeaux, D. Social Bookmarking                         What's this?

Efficacy of Daflon 500 mg in Venous Leg Ulcer Healing: A Double-Blind, Randomized, Controlled Versus Placebo Trial in 107 Patients

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Olivier Dereure, MD

Hospital Saint Charles Service de Dermatologie-Phlébologie 300 Rue A. Broussonnet 34295 Montpellier Cedex 5 France

Loïc Marzin, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Pierre Ouvry, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

François Zuccarelli, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Clélia Debure, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Hervé Van Landuyt, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Marie-Noëlle Gillet-Terver, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Bernard Guillot, PrMD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Hervé Levesque, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Jean Mignot, PhD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Gérard Pillion, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Benoit Février, MD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

Dominique Dubeaux, PharmD

Department of Service de Dermatologie-Phl6bologie, Hospital Saint Charles, Montpellier, France

The objective of this study was to evaluate the efficacy of Daflon® 500 mg (Dios)* in venous ulcers. A multicenter, double-blind, randomized, controlled versus placebo (Plac) trial was conducted, with stratification according to the size of ulcer ( 10 cm and > 10 cm). The protocol called for a two-month treatment with Dios (one tablet = 450 mg micronized purified Diosmin) or a placebo, two tablets/day, in addition to compression therapy.

Evaluations were performed every fifteen days, from DO to D60. The primary endpoint, in accordance with Alexander House group requirements were: percentage of patients with complete ulcer healing, ie, comparison between Dios and Plac group at D60, and comparison of survival curves in each group between DO and D60 (log rank test). Secondary endpoints included ulcer surface area assessed by computerized plani metric measurements, qualitative evaluation of ulcers, and symptoms.

The patients were 105 men and women ranging in age from eighteen to eighty-five years, with standard compression stocking, who were undergoing standardized local care of ulcer and had no significant arterial disease (ankle/arm systolic pressure index > 0.8). Fifty-three patients received Dios, and 52 received Plac. The 2 groups were well matched for age (m ±1 SD = seventy-one ±eleven years), gender, ulcer size, and associated disorders.

Among patients with ulcer size 10 cm (Dios = 44, Plac = 47) a significantly larger number of patients had a complete ulcer healing at two months in the Dios group (n = 14) in comparison with the Plac group (n = 6) (32% vs 13%, P = 0.028) with a signifi cantly shorter time duration of healing (P = 0.037). No difference was shown for the secondary criteria, except for sensation of heavy legs (P = 0.039) and a less atonic aspect of ulcer (P = 0.030) in favor of Dios. Among the 14 patients with ulcer size > 10 cm (Dios = 9, Plac = 5), subjected to a descriptive analysis only, no ulcer healed.

This study showed that a two-month course of Daflon 500 mg at a daily dose of two tablets, in addition to conventional treatment, is of benefit in patients with venous ulcer 10 cm by accelerating complete healing.

Angiology, Vol. 48, No. 1, 77-85 (1997)
DOI: 10.1177/000331979704800113


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. J. Bergan Chronic Venous Insufficiency and the Therapeutic Effects of Daflon 500 mg Angiology, November 1, 2005; 56(1_suppl): S21 - S24. [Abstract] [PDF]

				P. C. Smith Daflon 500 mg and Venous Leg Ulcer: New Results From a Meta-Analysis Angiology, November 1, 2005; 56(1_suppl): S33 - S39. [Abstract] [PDF]

				P. D. C. Smith From Skin Disorders to Venous Leg Ulcers: Pathophysiology and Efficacy of Daflon 500 mg in Ulcer Healing Angiology, July 1, 2003; 54(1_suppl): S45 - S50. [Abstract] [PDF]

				P. D. Coleridge Smith Update on Chronic-Venous-Insufficiency-Induced Inflammatory Processes Angiology, August 1, 2001; 52(1_suppl): S35 - S42. [Abstract] [PDF]

				J. J. Bergan, G. W. Schmid-Schonbein, and S. Takase Therapeutic Approach to Chronic Venous Insufficiency and its Complications: Place of Daflon(R) 500 mg Angiology, August 1, 2001; 52(1_suppl): S43 - S47. [Abstract] [PDF]

				A. A. Ramelet Clinical Benefits of Daflon 500 mg in the Most Severe Stages of Chronic Venous Insufficiency Angiology, August 1, 2001; 52(1_suppl): S49 - S56. [Abstract] [PDF]